- FoI Number
- 2024-796
- Subject
- Cancer Treatments
- Date Received
- 21/03/2025
- Request and Response
-
- How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months?
2
- If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?
- How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
- Paclitaxel in combination with a platinum-based compound
2
- Platinum-based therapy alone (cisplatin or carboplatin)
- Bevacizumab in combination with paclitaxel and carboplatin
- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Rucaparib
- Does your trust participate in any clinical trials for the treatment of ovarian cancer?
No
- If so, please provide the name of each trial along with the number of patients taking part
- If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:
- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Other treatments
